Orlistat interactions

Conditions

Conditions in which Orlistat needs care, as documented in this source.

• Malabsorption Syndromes

  Major

  The use of orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Orlistat can worsen the malabsorption in these conditions by reversibly inhibiting lipases that are necessary for the hydrolysis of triglycerides into absorbable free fatty acids and monoglycerides. At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.

  1 source

  1. "Product Information. Xenical (orlistat)." Roche Laboratories (2001):

• Diabetes Mellitus, Type 2

  Moderate

  Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight. Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.

  9 sources

  1. "Product Information. Fastin (phentermine)." SmithKline Beecham (2001):
  2. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company (2001):
  3. "Product Information. Xenical (orlistat)." Roche Laboratories (2001):
  4. "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
  5. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
  6. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
  7. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim (2001):
  8. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):

  Show all 9 sourcesShow fewer sources

  9. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals (2001):

• Fat Soluble Vitamin Deficiency

  Moderate

  At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% and has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. Therapy with orlistat should be administered cautiously in patients with preexisting deficiency of one or more fat-soluble vitamins (A, D, E and K). Ideally, the deficiency should be corrected prior to initiation of therapy. A multivitamin supplement containing fat-soluble vitamins is recommended during therapy, best taken once a day at least 2 hours before or after the administration of orlistat.

  1 source

  1. "Product Information. Xenical (orlistat)." Roche Laboratories (2001):

• Nephrolithiasis

  Moderate

  Following treatment with orlistat, some patients may develop increased levels of urinary oxalate as a result of fat malabsorption. Therapy with orlistat should be administered cautiously in patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.

  1 source

  1. "Product Information. Xenical (orlistat)." Roche Laboratories (2001):